For 2 decades fluoroquinolones have been found to be generally well-tolerat
ed and safe. Adverse events may be inherent to the class or influenced by s
tructural modifications. The commonest adverse events are gastrointestinal
tract (GI) and central nervous system (CNS) reactions; nephrotoxicity and t
endinitis are infrequent, but agents differ greatly in phototoxic potential
. Fluoroquinolones are safe in elderly, human immunodeficiency virus-infect
ed, and neutropenic patients, but because of possible effects on articular
cartilage, they are not currently recommended for children or pregnant wome
n. Four new agents have recently been licensed. Levofloxacin causes few GI
or CNS adverse events and is minimally phototoxic. Sparfloxacin infrequentl
y causes GI or CNS effects but is associated with relatively high rates of
phototoxicity and prolongation of the electrocardiographic QT(c) interval (
Q-T interval, corrected for head rate). Grepafloxacin causes relatively hig
h rates of GI effects, taste perversion, and QT(c) interval prolongation, b
ut it is minimally phototoxic. Trovafloxacin is associated with a moderate
rate of GI effects and a relatively high incidence of dizziness but has low
phototoxic potential.